Biofrontera Inc (BFRI) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Biofrontera Inc stock $0.30, price $0.83, that is 64.1% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range $0.5620 – $263.40 · fair‑value band $0.2210 – $0.4505 · the $0.8280 price screens above the $0.2975 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Biofrontera in your weekly email
Every Wednesday you see whether Biofrontera is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Show moreShow less
It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Stock analysis
Biofrontera Inc (BFRI) currently trades at $0.8280, while our model-based Fair Value estimate is $0.2975, 64% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.2210 (bear) to $0.4505 (bull), the price of $0.8280 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Biofrontera Inc reported revenue of $41.7M in FY2025 versus $24.1M in FY2021, a compound +14.7%/yr. Reported net income was −$10.5M in FY2025.
Key figures
Market cap $11.7M Micro · P/S ratio 0.29 · EPS (TTM) $−0.4300 · Net margin −13.8% · Return on equity −988% · Return on assets (EBIT) −55.0% (5-year average) · Operating margin −4.4% · Revenue (TTM) $46.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −64%, BFRI screens richer than that median.
Fair Value models
Bear$0.2210Fair Value $0.2975Bull$0.4505
Price $0.8280 · Downside -64.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.2600$0.3500$0.530053
All 1 models by family
Asset-Based
NCAV (Graham)$0.2600$0.3500$0.530053
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−51.0% (2020) → −21.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−64.1% · Bottom 25%
Profitability
Return on assets−36.9% · Bottom 25%
Net margin (12 months)−13.8% · Bottom 25%
Operating margin (12 months)−4.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)32.9% · Top 25%
Balance sheet
Debt / equity0.44× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B1.12× · Cheaper than median
P/S (12 months)0.25× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)100· sector 25
PAST (return on equity)0· sector 29
HEALTH (low debt)78· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biofrontera Inc Fair Value". https://www.fairvalue-calculator.com/stock/BFRI
Frequently asked questions
Is Biofrontera Inc (BFRI) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $0.2975 versus a price of $0.8280, about 64% lower (overvalued).
What is the fair value of BFRI?
Our model-based fair value for Biofrontera Inc is $0.2975 (as of Nov 4, 2026), built from audited fundamentals. The current price: $0.8280.
What is the quality score of BFRI?
Biofrontera Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biofrontera Inc (BFRI)?
Our model-based price target is the fair value of $0.2975 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario $0.2210, optimistic scenario $0.4505. It is a calculation from audited fundamentals, not an analyst target.
What is the Biofrontera Inc stock forecast for 2026?
Our models put fair value at $0.2975, about 64% lower versus a price of $0.8280 (overvalued). Cautious scenario $0.2210, optimistic scenario $0.4505. The calculation is refreshed regularly with new filings.
What is the revenue of Biofrontera Inc (BFRI)?
Biofrontera Inc reported trailing-twelve-month revenue of about $46.2M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Biofrontera Inc (BFRI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biofrontera Inc it is $0.2975 per share (as of Nov 4, 2026), against a price of $0.8280. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Biofrontera Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, BFRI trades above its calculated fair value: price $0.8280, fair value $0.2975, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BFRI?
No. The price is what the market pays today ($0.8280); the fair value is what the company's own numbers justify ($0.2975). For Biofrontera Inc the two are $0.5305 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biofrontera Inc worth?
The market values Biofrontera Inc at about $11.7M (market capitalisation, as of Nov 4, 2026). Per share that is $0.8280; our models calculate a fair value of $0.2975 per share.
What do the bullish and bearish scenarios say about BFRI?
Our models span a range for Biofrontera Inc: cautious scenario $0.2210, base $0.2975, optimistic $0.4505 per share (as of Nov 4, 2026, price $0.8280). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biofrontera Inc (BFRI)?
Balance-sheet figures for Biofrontera Inc (as of Nov 4, 2026): debt of 0.44 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is BFRI from its 52-week high?
Biofrontera Inc trades at $0.8280, about 49% below its 52-week high of $1.61 and 45% above the low of $0.5700 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2975 is for.
Which stocks are comparable to Biofrontera Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biofrontera Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $0.8280, calculated fair value $0.2975 (−64%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BFRI calculated?
We run Biofrontera Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.2975 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Biofrontera Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biofrontera Inc (BFRI)?
The closing price on Nov 6, 2026 was $0.8280. Our model-based fair value is $0.2975, about 64% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biofrontera Inc right now?
The price sits above even our optimistic bull case ($0.4505). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2210 to $0.4505) leaves room in how you read the outcome.
Key figures of Biofrontera Inc
How large is the market capitalisation of Biofrontera Inc (BFRI)?
The market capitalisation of Biofrontera Inc is $11.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biofrontera Inc (BFRI)?
The price-to-sales ratio of Biofrontera Inc is 0.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biofrontera Inc (BFRI)?
Earnings per share at Biofrontera Inc are $−0.4300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biofrontera Inc (BFRI)?
The net margin of Biofrontera Inc is −13.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biofrontera Inc (BFRI)?
The return on equity (ROE) of Biofrontera Inc is −988% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biofrontera Inc (BFRI)?
On an EBIT basis the return on assets of Biofrontera Inc is −55.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biofrontera Inc (BFRI)?
The operating margin of Biofrontera Inc is −4.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biofrontera Inc (BFRI)?
Revenue at Biofrontera Inc is growing +32.9% versus a year earlier (3y avg +13.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Biofrontera Inc (BFRI) generate?
The free cash flow of Biofrontera Inc is −$13.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biofrontera Inc (BFRI) hold?
Biofrontera Inc holds more cash than debt, $231K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Biofrontera Inc in the live analysis
One click puts Biofrontera Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
